GnRH Reference Compound

Description

Chemical Identity

GnRH Reference Compound analytical reference compound. Molecular weight 1182.29 Da. Research status: Discontinued.

Research Overview

GnRH Reference Compound is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). It stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary and is used clinically for diagnostic testing of pituitary gonadotroph function.

Overview. GnRH Reference Compound (GnRH) is a hypothalamic decapeptide agonist for the type I GnRH receptor (GnRHR) on anterior pituitary gonadotrophs. Binding triggers predominantly Gq/11-mediated signaling to phospholipase Cβ (PLCβ), generating IP3 and DAG, elevating cytosolic Ca2+ and activating protein kinase C (PKC). These proximal signals drive exocytosis of stored LH/FSH and activate downstream kinases and transcription factors that regulate LHB, FSHB, and CGA gene expression. Temporal patterning of GnRH exposure (pulsatile versus continuous) is a defining determinant of output and desensitization. Structurally, mammalian type I GnRHR lacks a cytoplasmic C‑terminal tail, shaping arrestin engagement and internalization kinetics.

Receptor interactions and structural determinants. The human type I GnRHR is a seven‑transmembrane rhodopsin‑like GPCR with a very short/absent C‑terminal cytoplasmic tail. Tail absence reduces agonist‑induced receptor phosphorylation, β‑arrestin docking, and rapid desensitization/internalization. Nevertheless, internalization occurs via clathrin pathways with species-specific dynamin dependence (rat dynamin‑dependent; human dynamin‑independent). Key residues include N87 (critical for ligand binding/signaling), D318 (required for coupling to IP3 production), and S140 (variant of the DRY motif; restoring Y increases affinity/internalization). Lys191 in the second extracellular loop reduces plasma‑membrane expression in primates by promoting misfolding/ER retention. In several mammals (including humans), the type II GnRHR (GnRHR2) is nonfunctional/truncated; GnRH‑II actions are mediated via type I receptors.

Therapeutic applications and documented outcomes of GnRH Reference Compound (GnRH) span fertility induction in hypogonadotropic hypogonadism, pubertal/testicular development, diagnostic stimulation of the HPG axis, and emerging neuromodulatory investigation. The most robust evidence is in male fertility induction using pulsatile administration.

Key published studies on GnRH Reference Compound include: “Use of pulsatile GnRH in patients with functional hypothalamic amenorrhea results in monofollicular ovulation and high cumulative live birth rates” (Journal of Assisted Reproduction and Genetics, 2022); “Pulsatile gonadotropin-releasing hormone therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism” (Asian Journal of Andrology, 2017); “Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome” (Cochrane Database of Systematic Reviews, 2004). These findings should be interpreted within the context of the experimental models and conditions described in each publication.

Research Context

Primary G protein coupling and proximal signaling. In pituitary gonadotrophs the GnRHR predominantly couples to Gαq/11, activating PLCβ to hydrolyze PIP2 into IP3 and DAG. IP3 releases Ca2+ from endoplasmic reticulum stores (initial spike), while DAG activates PKC and promotes activation of L‑type voltage‑gated Ca2+ channels generating sustained Ca2+ influx (plateau). The combined Ca2+/PKC signals are necessary for secretion and for activation of downstream MAPK pathways.

Downstream kinase cascades and transcriptional effectors. GnRH activates multiple MAPK modules—ERK1/2, JNK, p38, and ERK5. ERK1/2 activation in gonadotrophs requires extracellular Ca2+ influx and is facilitated by calmodulin‑sensitive Pyk2/Src→Ras→Raf→MEK signaling; it drives nuclear Elk‑1 phosphorylation and induction of Egr‑1 and c‑Fos, promoting LHB transcription. JNK activation depends more on Ca2+ release from stores and PKC/cdc42, with JNK/p38 phosphorylating ATF‑2 and AP‑1 components (e.g., c‑Jun). ERK5 activity has been implicated in FSHB regulation. In parallel, Ca2+/calmodulin activates calcineurin to dephosphorylate NFAT, enabling NFAT nuclear accumulation and contribution to FSHB control. Collectively these pathways regulate CGA, LHB, and FSHB promoters in a promoter‑ and context‑specific manner.

Cyclic nucleotides and cross‑talk. Although Gq/11→PLC is primary, GnRH can modulate cyclic nucleotide pathways. In some gonadotroph contexts GnRH elevates cAMP via Gs and/or Ca2+/calmodulin‑sensitive adenylyl cyclases (AC5/7), activating PKA and CREB; low‑frequency pulses preferentially enhance CREB phosphorylation and FSHB expression. GnRH also influences cGMP: it can induce NOS/NO→soluble guanylyl cyclase to raise cGMP, and via PKC it can inhibit CNP/NPRB‑stimulated cGMP. Cross‑talk with PACAP is prominent: PACAP strongly elevates cAMP in gonadotrophs and can synergize with GnRH, while PKC activation by GnRH can dampen PACAP‑stimulated cAMP, integrating signals across pathways.

Specifications

Each lot is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing results.

Research Applications

GnRH Reference Compound reference compound has been documented in the published scientific literature across the following in vitro and preclinical research areas:

• Diagnostic testing of hypothalamic-pituitary-gonadal axis
• Fertility treatment support
• Hormone replacement therapy adjunct
• Research into reproductive endocrinology

Researchers are advised to consult the primary literature for detailed experimental protocols, concentrations, and conditions relevant to their specific area of investigation involving GnRH Reference Compound.

Storage and Handling

GnRH Reference Compound is supplied as a lyophilized powder and should be stored at -20°C upon receipt for long-term stability. Protect from light, moisture, and repeated temperature fluctuations. Allow the sealed vial to equilibrate to room temperature before opening to prevent condensation and moisture absorption.

For reconstitution, add sterile water or an appropriate buffer slowly along the vial wall to avoid foaming. Gently swirl to dissolve — do not vortex. Reconstituted GnRH Reference Compound solutions should be stored at 2-8°C and used within 30 days. Aliquoting is recommended to minimize freeze-thaw cycles. Consult the Safety Data Sheet (SDS) for detailed handling and disposal guidance.

For laboratory research use only (in vitro). Not for human or animal use. Not for diagnostic, therapeutic, or clinical purposes. GnRH Reference Compound is supplied as an analytical reference compound for use by qualified research personnel at accredited institutions. Prescott Bio Canada does not provide guidance on administration, dosing, or use in living organisms.